4D Molecular Therapeutics (FDMT) Competitors $3.34 -0.03 (-0.86%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FDMT vs. PHAR, VALN, ORGO, CRMD, OPT, UPB, BCYC, IMTX, PRTA, and KURAShould you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Pharming Group (PHAR), Valneva (VALN), Organogenesis (ORGO), CorMedix (CRMD), Opthea (OPT), Upstream Bio (UPB), Bicycle Therapeutics (BCYC), Immatics (IMTX), Prothena (PRTA), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. 4D Molecular Therapeutics vs. Pharming Group Valneva Organogenesis CorMedix Opthea Upstream Bio Bicycle Therapeutics Immatics Prothena Kura Oncology Pharming Group (NASDAQ:PHAR) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability. Does the MarketBeat Community favor PHAR or FDMT? 4D Molecular Therapeutics received 33 more outperform votes than Pharming Group when rated by MarketBeat users. However, 67.65% of users gave Pharming Group an outperform vote while only 65.12% of users gave 4D Molecular Therapeutics an outperform vote. CompanyUnderperformOutperformPharming GroupOutperform Votes2367.65% Underperform Votes1132.35% 4D Molecular TherapeuticsOutperform Votes5665.12% Underperform Votes3034.88% Do analysts rate PHAR or FDMT? Pharming Group presently has a consensus target price of $30.00, suggesting a potential upside of 241.49%. 4D Molecular Therapeutics has a consensus target price of $26.71, suggesting a potential upside of 699.59%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Pharming Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.004D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, PHAR or FDMT? Pharming Group has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500. Is PHAR or FDMT more profitable? 4D Molecular Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -6.09%. Pharming Group's return on equity of -7.65% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-6.09% -7.65% -3.82% 4D Molecular Therapeutics N/A -28.00%-26.16% Do insiders and institutionals hold more shares of PHAR or FDMT? 0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to PHAR or FDMT? In the previous week, Pharming Group had 3 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 8 mentions for Pharming Group and 5 mentions for 4D Molecular Therapeutics. Pharming Group's average media sentiment score of 0.75 beat 4D Molecular Therapeutics' score of 0.49 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, PHAR or FDMT? Pharming Group has higher revenue and earnings than 4D Molecular Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$297.20M2.01-$10.55M-$0.17-51.684D Molecular Therapeutics$37K4,180.95-$100.84M-$2.98-1.12 SummaryPharming Group and 4D Molecular Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FDMT vs. The Competition Export to ExcelMetric4D Molecular TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.34M$2.96B$5.51B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.1830.1522.5518.49Price / Sales4,180.95494.70394.97102.66Price / CashN/A168.6838.1834.62Price / Book0.463.166.694.25Net Income-$100.84M-$72.35M$3.22B$248.31M7 Day Performance2.80%0.47%1.11%1.12%1 Month Performance11.74%7.67%3.59%3.68%1 Year Performance-86.84%-22.98%15.65%5.19% 4D Molecular Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FDMT4D Molecular Therapeutics2.6172 of 5 stars$3.34-0.9%$26.71+699.6%-85.9%$155.34M$37,000.00-1.18120Upcoming EarningsNews CoverageGap UpPHARPharming Group2.5191 of 5 stars$8.15+0.7%$30.00+268.1%-6.6%$554.45M$297.20M-31.35280Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap UpVALNValneva2.523 of 5 stars$6.63-2.4%$16.00+141.3%-14.9%$538.76M$169.58M-51.00700Upcoming EarningsShort Interest ↓ORGOOrganogenesis3.4237 of 5 stars$4.21-0.2%$5.50+30.6%+108.9%$533.95M$482.04M-70.17950Upcoming EarningsNews CoveragePositive NewsCRMDCorMedix2.5011 of 5 stars$8.14+6.1%$14.50+78.1%+74.9%$530.58M$43.47M-10.0530Upcoming EarningsPositive NewsOPTOpthea0.9143 of 5 stars$3.41+7.2%$1.33-60.9%-0.6%$524.84M$87,666.000.008Gap UpUPBUpstream BioN/A$9.71+10.6%$56.50+481.9%N/A$520.85M$2.37M0.0038News CoveragePositive NewsBCYCBicycle Therapeutics3.0388 of 5 stars$7.51+1.6%$29.14+288.1%-63.5%$519.71M$35.28M-2.28240Earnings ReportShort Interest ↓Positive NewsIMTXImmatics2.0596 of 5 stars$4.24-0.5%$16.67+293.1%-49.6%$515.37M$155.84M-6.42260Positive NewsPRTAProthena3.4204 of 5 stars$9.30+1.1%$55.00+491.4%-54.8%$500.59M$135.16M-4.04130Upcoming EarningsGap DownKURAKura Oncology4.1485 of 5 stars$6.18+4.7%$25.50+312.6%-66.6%$499.21M$53.88M-2.62130Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies PHAR Alternatives VALN Alternatives ORGO Alternatives CRMD Alternatives OPT Alternatives UPB Alternatives BCYC Alternatives IMTX Alternatives PRTA Alternatives KURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FDMT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FDMT Stock Free FDMT Stock Alerts